NEW YORK (GenomeWeb News) – Rosetta Genomics will work with the Rabin Medical Center in Israel to develop microRNA-based tests for women’s health, the company said today.
The company plans to use microRNA biomarkers to develop “a wide range of diagnostic and prognostic tests” in oncology, gynecology, and obstetrics, the Rehovot, Israel-based company said.
"There is true unmet medical need for better diagnostics in women's health, and I am confident that the Rabin Medical Center's world-renowned researchers will assist us in bringing better diagnostics to patients worldwide,” Rosetta Genomics CEO Amir Avniel said in a statement.
The Rabin Medical Center, comprised of the Beilinson and Hasharon Hospitals, is headquartered near Tel Aviv, and many of its medical and research staff hold posts at the Tel Aviv University Sackler School of Medicine.